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2. X-ray screening, and
3. Two week run-in period
Telephone screening was comprehensive and included questions on age,
seafood allergies, co-morbidities (RA, bilateral knee replacements, unstable
diabetes, recent lower limb surgery or intra-articular injections), intention
to undergo joint replacement in next year, opioid use, informed that knee
is ‘bone-on-bone’, willingness to be randomised, willingness to adhere to
study procedures and level of knee pain ‘at its worst’ in the past week.
The subsequent radiographic screening required evidence of predominant
medial tibio-femoral joint disease but retaining at least 2 mm of medial
joint space width in a suﬃciently symptomatic (≥4 out of 10) knee. If still
eligible, a two week ‘run-in’ period required adherence to study treatment
capsules and return of a completed Participant Diary.
Results: From an initial 2,682 telephone enquiries, 605 people were
randomised (October 2007-2009). The main barrier to recruitment was
unwillingness to be randomised to placebo (Figure 1).
Figure 1. Recruitment ﬂowchart.
Fifty percent of the radiographic ineligibility was due to complete loss of
medial tibio-femoral joint space. A further 13% withdrew from participation
during the ‘run-in’ period. The baseline demographics of the LEGS study
cohort (Table1) demonstrate the required screening pain of ≥4 out of 10
was not maintained at the subsequent baseline assessment (WOMAC) or
7-day Participant Diary by many participant.
Table 1. Baseline demographics
N=605 n, % Pain and disability Mean (sd)
Age mean (sd) 60.3 (8.2) WOMAC pain (0-100) 33.2 (17.6)
BMI mean (sd) 28.9 (5.8) WOMAC function (0-100) 32.4 (18.2)
Female 339, 56% SF-12 PCS 41.3 (9.5)
Obese 214, 35% SF-12 MCS 52.8 (10.0)
No comorbidity 73, 12% Mean pain over 7-days (0-10) 3.5 (1.8)
High blood pressure 195, 32% Max pain over 7-days (0-10) 4.6 (2.1)
Back pain 138, 23%
Stomach problems 67, 11%
Depression 62, 10%
Heart Disease 55, 9%
Diabetes 35, 6%
Paracetamol for knee pain 211, 35%
NSAIDs for knee pain 119, 20%
Conclusions: A comprehensive telephone screening reduced the burden
of radiographic screenings. The two week ’run- in’ of study procedures
further reduced the number of participants likely to drop out soon after
randomisation. It is diﬃcult to identify people with knee osteoarthritis that
have at least moderate ongoing pain, yet retain medial tibio-femoral joint
space width >2mm.
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Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the “Gold
Standards” in the treatments of various pain and inﬂammation related dis-
orders like arthritis. However, their oral administration and use of newer
selective COX-2 NSAIDs known to induce severe intolerance in patients.
Thus, the present work aims to compare the eﬃcacy and safety of a
epicutaneously applied diclofenac in novel liposomal gel vis-à-vis marketed
gel and placebo for relief of signs and symptoms in osteoarthritis (OA) of
knee.
Methods: This was a randomized, double-blind, controlled trial on 36 pa-
tients with knee osteoarthritis. They were randomly assigned to liposomal
gel, marketed gel and placebo, twice a day for 6 weeks. The patients
were assessed by primary eﬃcacy outcome measures included the changes
from baseline to end of study on the WOMAC (Western Ontario McMaster
Universities) Osteoarthritis Index. The radiographic imaging of OA in the
knee was also performed for Kellgren-Lawrence criteria. Safety of the gel
was also assessed by evaluating adverse events, vital signs, and irritation at
the application site.
Results: In liposomal gel treated group, the pain, stiffness and diﬃculty
performing routine activities showed statistically signiﬁcantly improve-
ments on 6 weeks of treatment compared to the other tested gels. While,
all the treatments were found to be well tolerated with no observed
adverse event.
Conclusions: Diclofenac in liposomal gel is superior to other tested formu-
lations viz. marketed gel and placebo in the relieving the symptoms of OA
of the knee. Hence, it can be concluded that diclofenac in liposomal gel can
be a rational alternative to oral diclofenac formulations for management of
various pain and inﬂammation related ailments including osteoarthritis.
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Purpose: The literature suggests ACL injuries and meniscal lesions are
associated with the development of knee osteoarthritis (OA). There is
limited evidence that surgical repair of these lesions diminishes future
development of knee OA. A review of the long-term consequences of these
injuries suggests that some 50% of those undergoing meniscectomy will
develop OA between10 to 20 years after the surgery. Estimates from the
literature indicate that 10% to 90% of individuals with ACL injury develop
OA within 10 to 20 years of the lesion. This raises the question as to
what proportion of all knee OA cases might be associated with previous
arthroscopic surgery.
Methods: A study to estimate the proportion of individuals who will
develop OA after having arthroscopic surgery was designed by juxtaposing
data form different sources. (a) Data on the age- and sex-speciﬁc rates of
arthroscopic surgery (closed repair of the knee which includes menisec-
tomy and ACL repairs) in Ontario, Canada for the population aged 5-45
years, (b) data on the age and sex incidence of OA estimated from physician
billing data in British Columbia, Canada, (c) Population data for Canada,
and d) estimates of the proportion of individuals with arthroscopic surgery
who develop OA were combined to calculate estimates of the number of
incident OA cases likely due to arthroscopic surgery at the end of a 10 year
period. The rates of arthroscopic surgery were applied to the population to
estimate the number of individuals with this type of surgery. OA incidence
rates were also applied to the population to estimate the number of new
OA cases every year. The following scenarios for the proportion developing
OA over a period of 10 years were used: 10%, 20%, 30% and 40%. The main
assumptions made were: constant arthroscopic rates and incidence rates of
